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Background
We have previously shown that NK cells preferentially
target cancer stem cells (CSCs) in diverse human solid
malignancies and that radiotherapy (RT) enhances NK
targeting of CSCs in an NKG2D-dependent manner. We
hypothesized that dog PBMC-derived NK cells could be
similarly expanded and activated ex vivo for combina-
tion radioimmunotherapy in canine models of sarcoma.
Methods
Dog NK cells were isolated from fresh PBMCs using Ficoll
separation and CD5 depletion. Isolated NK cells (CD3+,
CD5dim, TCR-) were expanded via co-culture with irra-
diated (100Gy) K562-C9-mIL-21 for 2-3 weeks in 100IU/
mL recombinant human IL-2. Canine osteosarcoma
(OSCA) tumor lines and fresh canine primary sarcomas
were evaluated for susceptibility to NK killing before/after
RT in vitro and in xenograft experiments with NSG mice.
NK cytotoxicity was assessed in 4-16 hour killing assays by
Flow cytometry using a BD Fortessa cell sorter (BD Bios-
ciences) with 7-Aminoactinomycin as cell viability marker.
Results
NK expansion was successful in 14/20 donors (including
9 tumor-bearing dogs) from baseline 4.5(±1.9) ×106 cells
to 103.5(±29.1) ×106, mean increase 23.2X (±2.3). Canine
NK cells were also responsive to human cytokines (IL-2,
IL-12, and IL-18), but expansions were lower (1.6-3.5
fold expansion over 14 days). NK cytotoxicity to
OSCA78, OSCA23, and NK-sensitive CTAC cells in vitro
increased in a dose-dependent fashion reaching 74 – 88%
cytolysis at effector:target ratios of 10:1 – 20:1 (P <
0.001). RT augmented NK cytotoxicity with greatest
synergy at 2.5-5 Gy RT in 4-hour killing assays (1.3-3.4X
increased killing, P < 0.01). At doses of 10 Gy and/or16-
hour killing assays, only minor differences in overall
killing were observed. Similar results were observed
with RT sensitization to NK killing in primary canine
sarcomas. In a dog sarcoma PDX model using focal RT,
intravenous NK transfer, and hydrodynamic human IL-15
for in vivo NK support, focal RT increased NK homing to
tumors by 3.8X±0.3 (P < 0.001).
Conclusions
RT enhances NK homing and killing in canine models
of STS. Dog STS appears to be a valuable model to
facilitate clinical translation of NK radioimmunotherapy.
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